Automate Your Wheel Strategy on PEN
With Tiblio's Option Bot, you can configure your own wheel strategy including PEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PEN
- Rev/Share 34.1314
- Book/Share 34.7685
- PB 10.2392
- Debt/Equity 0.1597
- CurrentRatio 6.7305
- ROIC 0.0959
- MktCap 13965762520.0
- FreeCF/Share 3.9055
- PFCF 91.5062
- PE 84.8147
- Debt/Assets 0.1244
- DivYield 0
- ROE 0.1308
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | PEN | JP Morgan | Neutral | Overweight | -- | $370 | Dec. 18, 2025 |
| Upgrade | PEN | Citigroup | Neutral | Buy | -- | $350 | Dec. 11, 2025 |
| Initiation | PEN | Wells Fargo | -- | Underweight | -- | $15 | Nov. 18, 2025 |
| Upgrade | PEN | Needham | Hold | Buy | -- | $326 | Oct. 8, 2025 |
| Initiation | PEN | Evercore ISI | -- | Outperform | -- | $300 | Sept. 2, 2025 |
| Initiation | PEN | BofA Securities | -- | Buy | -- | $320 | March 14, 2025 |
| Initiation | PEN | UBS | -- | Buy | -- | $305 | Jan. 21, 2025 |
| Initiation | PEN | Oppenheimer | -- | Outperform | -- | $275 | Dec. 17, 2024 |
| Upgrade | PEN | Wells Fargo | Equal Weight | Overweight | $190 | $275 | Dec. 11, 2024 |
| Initiation | PEN | Stifel | -- | Buy | -- | $238 | Sept. 18, 2024 |
News
GMED vs. PEN: Which Stock Is the Better Value Option?
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Penumbra (PEN). But which of these two stocks is more attractive to value investors?
Read More
Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights
Published: January 27, 2026 by: GlobeNewsWire
Sentiment: Neutral
Shareholders should contact the firm as there may be limited time to enforce your rights Shareholders should contact the firm as there may be limited time to enforce your rights
Read More
Artisan Small Cap Fund Q4 2025 Portfolio Activity
Published: January 23, 2026 by: Seeking Alpha
Sentiment: Neutral
During the quarter, we initiated new positions in nLIGHT, Guardant Health and Cellebrite. We also added to Bruker, Hexcel and Penumbra during the quarter. Along with Insmed, we also ended our investment campaigns in Integer Holdings and SharkNinja during the quarter.
Read More
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN
Published: January 16, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK and NEW ORLEANS, Jan. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Read More
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Penumbra, Inc. (NYSE: PEN)
Published: January 15, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Penumbra, Inc. (NYSE: PEN) related to its sale to Boston Scientific Corporation.
Read More
Boston Scientific to acquire Penumbra in $14.5B deal
Published: January 15, 2026 by: Proactive Investors
Sentiment: Positive
Boston Scientific Corp (NYSE:BSX, XETRA:BSX) announced a definitive agreement to acquire medical device company Penumbra (NYSE:PEN) in a cash and stock transaction valuing Penumbra at $374 per share, or approximately $14.5 billion in enterprise value. Penumbra shares rose almost 12% on the news to about $350, while Boston Scientific shares fell 4.5% to about $90.
Read More
Shareholder Alert: The Ademi Firm investigates whether Penumbra, Inc. is obtaining a Fair Price for its Public Shareholders
Published: January 15, 2026 by: PRNewsWire
Sentiment: Neutral
MILWAUKEE, Jan. 15, 2026 /PRNewswire/ -- Ademi LLP is investigating Penumbra (NYSE: PEN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Boston Scientific. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.
Read More
CLPBY vs. PEN: Which Stock Is the Better Value Option?
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Instruments stocks have likely encountered both Coloplast A/S Sponsored ADR (CLPBY) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Read More
Here's Why Penumbra (PEN) is a Strong Growth Stock
Published: December 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here's Why Penumbra (PEN) is a Strong Growth Stock
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
GMED or PEN: Which Is the Better Value Stock Right Now?
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Instruments stocks have likely encountered both Globus Medical (GMED) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Penumbra, Inc. (PEN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Penumbra, Inc. (PEN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Read More
Here's Why Penumbra (PEN) is a Strong Growth Stock
Published: November 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism
Published: November 03, 2025 by: PRNewsWire
Sentiment: Neutral
The STORM-PE RCT data presented at the VIVA 2025 Conference showed PE patients treated with CAVT in combination with anticoagulation demonstrated significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to those who received only anticoagulation Results of STORM-PE demonstrating superior efficacy of CAVT with anticoagulation versus anticoagulation alone were also published in Circulation today ALAMEDA, Calif. , Nov. 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced additional results of the ground-breaking STORM-PE randomized controlled trial (RCT), which found that the use of computer assisted vacuum thrombectomy (CAVT™) with anticoagulation achieved significantly greater …
Read More
Can Penumbra's 'Landmark' Study Vs. Blood Thinners Change Guidelines?
Published: October 26, 2025 by: Investors Business Daily
Sentiment: Positive
Penumbra unveiled the results of a study on Sunday showing its device is superior to blood thinners in pulmonary embolism patients.
Read More
ITGR or PEN: Which Is the Better Value Stock Right Now?
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Instruments stocks are likely familiar with Integer (ITGR) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
TFX vs. PEN: Which Stock Should Value Investors Buy Now?
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?
Read More
Penumbra, Inc. (PEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Penumbra, Inc. (NYSE:PEN ) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 8:45 AM EDT Company Participants Adam Elsesser - Co-Founder, Chairman & CEO Shruthi Narayan - President Conference Call Participants Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Presentation Larry Biegelsen Senior Medical Device Equity Research Analyst All right. Good morning, everyone.
Read More
Why Is Penumbra (PEN) Up 5% Since Last Earnings Report?
Published: August 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock?
Read More
Penumbra, Inc. Names Shruthi Narayan as Company President
Published: August 27, 2025 by: PRNewsWire
Sentiment: Neutral
ALAMEDA, Calif. , Aug. 27, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced the promotion of Shruthi Narayan to President of the company, effective September 1, 2025.
Read More
ITGR or PEN: Which Is the Better Value Stock Right Now?
Published: August 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in Medical - Instruments stocks are likely familiar with Integer (ITGR) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Penumbra, Inc. (PEN) Q2 2025 Earnings Call Transcript
Published: July 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Penumbra, Inc. (NYSE:PEN ) Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Adam Elsesser - Co-Founder, Chairman, President & CEO Cecilia Furlong - Corporate Participant Jason Richard Mills - Executive Vice President of Strategy Maggie S. Yuen - Chief Financial Officer Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C.
Read More
Penumbra (PEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Penumbra (PEN) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.64 per share a year ago.
Read More
ITGR vs. PEN: Which Stock Is the Better Value Option?
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer (ITGR) or Penumbra (PEN). But which of these two stocks is more attractive to value investors?
Read More
Will Penumbra (PEN) Beat Estimates Again in Its Next Earnings Report?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Penumbra (PEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
About Penumbra, Inc. (PEN)
- IPO Date 2015-09-18
- Website https://www.penumbrainc.com
- Industry Medical - Devices
- CEO Adam Elsesser
- Employees 4500